Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
PacBio (NASDAQ: PACB) has joined the 1000 Genomes Long Read Sequencing Project to contribute long-read transcriptome data using its Kinnex RNA kits and Revio sequencing platform. The project will sequence approximately 1,000 samples from the 1000 Genomes cohort to provide transcript-level insights across diverse human populations.
In collaboration with researchers from the University of Washington and Johns Hopkins University, the project aims to generate around 10 million full-length transcript reads per sample. The initiative will create an open-access RNA resource and develop bioinformatics pipelines to support long-read transcriptomics research, with early findings to be presented at the upcoming ASHG conference.
QIAGEN (NYSE: QGEN) has launched QIAseq xHYB Long Read Panels, a new suite of target enrichment solutions designed for long-read sequencing of complex genomic regions. The panels are optimized for native long-read platforms, including PacBio's technology, and aim to improve analysis of structural variants, HLA typing, and repeat expansions.
Built on QIAGEN's hybrid-capture chemistry, the panels offer high target completeness, flexible formats including fixed panels for hereditary cancers and HLA typing, compatibility with high-molecular-weight DNA extraction kits, and integration with QIAGEN Digital Insights bioinformatics. The launch strengthens QIAGEN's position in providing solutions for both short- and long-read NGS technologies.
PacBio (NASDAQ: PACB), a biotechnology company, has scheduled its second quarter 2025 financial results conference call for Thursday, August 7, 2025, at 5:00 PM Eastern Time (2:00 PM Pacific Time). The earnings call will be accessible through a webcast on the company's investor relations website.
Participants can join via webcast or dial in using toll-free (1-888-349-0136) or international (1-412-317-0459) numbers. Those choosing to dial in are advised to join ten minutes before the start time.
PacBio (NASDAQ: PACB), a developer of high-quality sequencing solutions, has announced its participation in two major upcoming investor conferences. The company will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 8:45 AM ET in New York, and at the 46th Annual Goldman Sachs Global Healthcare Conference on June 11, 2025, at 10:40 AM ET in Miami Beach. Both presentations will be available via live webcasts on PacBio's investor relations website, with replays accessible for at least 30 days after each event.
PacBio (NASDAQ: PACB) has appointed Haorui Gene as an official distributor in China to expand access to its HiFi long-read sequencing technology. Haorui Gene, established in 2020, has become a leader in blood typing genomics with seven Sequel II and three Revio systems deployed across China. The company will distribute PacBio's Vega platform throughout China, focusing on transfusion medicine and hematology applications.
Haorui Gene has published over 20 peer-reviewed papers and gained widespread adoption in Chinese blood centers. The company introduced HiFi-based HLA typing products in 2022 and blood group genotyping panels in 2023. In 2024, they expanded collaborations with major blood centers for rare blood classification and erythrocyte antigen mapping research.
PacBio (NASDAQ: PACB) announced the conclusion of an independent investigation by the Special Committee of its Board of Directors regarding allegations from an employee affected by a recent workforce reduction. The investigation focused on employment practices and cybersecurity matters. The Special Committee found that the allegations were unsubstantiated, confirming no improper employment practices and no material inaccuracies in the company's cybersecurity disclosures in its 2024 Form 10-K. Board Chairman John Milligan expressed satisfaction with the investigation's conclusion.
PacBio (PACB) and Chulalongkorn University have announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) in a newborn screening research program in Thailand. This marks the first initiative in Asia Pacific to use PacBio's HiFi sequencing technology at population scale.
The collaboration aims to evaluate how comprehensive genomic data can support earlier identification of rare and treatable conditions in newborns. PacBio's HiFi WGS technology offers advantages over traditional screening methods by generating highly accurate genomic data, including regions typically inaccessible to short-read methods, while capturing epigenomic information in parallel.
This initiative positions Thailand as a regional leader in population-scale genomics and demonstrates Asia Pacific's growing influence in global genomics. The project aims to establish a scalable research model for genomic newborn screening, potentially serving as a blueprint for other countries seeking to modernize their screening programs.
PacBio (PACB) has announced plans to enhance its methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods from The Chinese University of Hong Kong (CUHK). The licensed technology includes the Holistic Kinetic Model 2 (HK2), an AI deep learning framework that will improve the detection of DNA base modifications including 5-hydroxymethylcytosine (5hmC) and hemimethylated 5-methylcytosine (5mC) in native DNA.
The enhanced capabilities will be implemented on PacBio's Revio and Vega systems through software updates, requiring no changes to sequencing protocols or additional costs. The technology enables simultaneous genome and epigenome readout from native DNA without chemical conversion or additional sample preparation. The HK2 model is designed to significantly improve accuracy in 5mC and N6-methyladenine (6mA) detection while introducing native 5hmC calling in single molecules.